Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

109.35 +0.95 (+0.88%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis Ag ADR

< Previous 1 2 3 4 5 6 7 8 9
...
42 43 Next >
Why Novartis Stock Is Down Today Despite Topping Q2 Estimates
Investors were caught off guard by a decision on the research and development front. 
Via The Motley Fool
VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday?
It’s another risk-off day on Wall Street, with all major U.S. indices trading in the red. The CBOE Volatility Index (VIX), often referred to as the market’s fear gauge, spiked over 10%, reaching levels... 
Via Benzinga
Topics Stocks
Exposures US Equities
Novartis' Q2 Earnings: Revenue And EPS Beat, Raises 2024 Profit Forecast On Strong Demand For Key Drugs
Novartis reports strong Q2 results with adjusted EPS of $1.97, up 21% YoY, and sales at $12.51 billion, up 11%. Key drivers include Entresto, Kesimpta, Cosentyx, Kisqali, Leqvio, and Pluvicto. The... 
Via Benzinga
Novartis Reports Near 40% Margin In Q2; Shares Slide
Novartis topped Q2 views and lifted guidance. Shares eased after a four-month run. 
Via Investor's Business Daily
Is NYSE:NVS a Good Fit for Dividend Investing?
Is NOVARTIS AG-SPONSORED ADR (NYSE:NVS) suited for dividend investing? 
Via Chartmill
Exploring NYSE:NVS's dividend characteristics.
Why NOVARTIS AG-SPONSORED ADR (NYSE:NVS) qualifies as a good dividend investing stock. 
Via Chartmill
Wall Street Gearing Up For Tech-Led Rebound Ahead Of Netflix Earnings: Economist Expects Soft Landing But Says Brace For Bigger Fed Rate Cuts If This Happens
Beaten-down stocks could make a comeback on Thursday, with Taiwan Semiconductor Manufacturing Company Ltd.’s (NYSE:TSM) strong quarterly repo 
Via Benzinga
Topics Economy
Exposures Interest Rates
Alnylam Stock Is a Blockbuster Biopharma In the Making
Alnylam stock could significantly pad its initial gains if vutrisiran gains expedited approval to hit the market. 
Via InvestorPlace
NVS Stock Earnings: Novartis Beats EPS, Beats Revenue for Q2 2024
NVS stock results show that Novartis beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
2 Magnificent Stocks to Buy With $500
These reliable healthcare companies look attractive no matter how you slice it. 
Via The Motley Fool
D.R. Horton, Netflix And 3 Stocks To Watch Heading Into Thursday
Via Benzinga
3 Global Stocks to Buy to Escape the Volatility on Wall Street
Discover three top global stocks as a smart hedge against Wall Street volatility, offering diversification and resilience in uncertain times. 
Via InvestorPlace
3 Spinoff Stocks You Should Buy Now: July 2024
Spinoff stocks often take time to gain their footing in the market giving investors an opportunity to get in early. 
Via InvestorPlace
The 7 Most Undervalued Healthcare Stocks to Buy in July 2024
Explore undervalued healthcare stocks offering growth potential and stability in contrast to overvalued tech sector. 
Via InvestorPlace
3 Healthcare Stocks Injecting AI for Big Gains
Investors should keep a close eye on these AI healthcare stocks as they revolutionize the future of drug development and patient care. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
The 3 Most Undervalued Pharma Stocks to Buy in July 2024
Pharma stocks can be great investments during times of growth and recession, and are made even better if the stock is undervalued. 
Via InvestorPlace
Topics Economy
Exposures Economy
Netflix, Goldman Sachs, J&J, ASML Lead Q2 Reports This Week As Analysts See Earnings Growth Accelerating To Fastest In Over 2 Years
Following a lackluster big bank earnings, market participants now turn their attention to the unfolding week, expecting the trend to reverse. 
Via Benzinga
Novartis Stock Generating Improved Relative Strength
Top and bottom line growth moved higher in Novartis' most recent quarter. EPS rose 17% to $1.80. Revenue increased 10% to $12.1 billion. 
Via Investor's Business Daily
Ozempic Maker Novo Nordisk Reprimanded by UK Regulators for Payment Disclosure Failures
UK regulators reprimand Novo Nordisk for failing to disclose nearly $10 million in fees and expenses. The PMCPA cites breaches in financial categorization and highlights similar issues with Novartis... 
Via Benzinga
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides. 
Via Investor's Business Daily
Upcoming Stock Spinoffs: Should You Pounce or Pass?
Stock spinoffs are a unique opportunity to pick up unloved, unwanted businesses but patience is often needed before buying in. 
Via InvestorPlace
Mississippi Judge Upholds State Law Mandating Drug Discounts for Low-Income Patients
A Mississippi judge upheld a state law requiring drugmakers to offer discounts on medications through third-party pharmacies for low-income populations, rejecting lawsuits from PhRMA and Novartis. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Superlab Suisse opens state-of-the-art facility in Basel, fostering new spaces for scientific breakthroughs
With this new facility, Superlab Suisse becomes the largest private lab space in Switzerland. 
Via News Direct
Novartis Stock Just Below Innovative Drugmaker's All-Time High; Gets Key Rating Upgrade
Novartis stock is in a buy range after moving past a 103.55 entry in a cup with handle. The buy range extends to 5% above the initial entry. 
Via Investor's Business Daily
Nestle Carefully Targets Weight-Loss Drug Users with New Food Line
Nestle's new Vital Pursuit brand targets individuals on weight-loss drugs without mentioning medications on packaging, addressing regulatory concerns and focusing on marketing through social media. 
Via Benzinga
German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount
Evotec consults defense advisers following a significant share price decline, raising concerns about a potential takeover. 
Via Benzinga
What's Going On With Neurological Disease Focused Trevena On Thursday?
Trevena shares dropped 33.7% to $0.23 with a session volume of 23.65 million. Notably, TRV045 did not cause S1P1R desensitization or protein reduction, unlike fingolimod. 
Via Benzinga
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities. 
Via InvestorPlace
3 Crazy Good Stocks to Buy With $500 Right Now
For investors with only a little money to spare, these three supercharged stocks represent an outrageous opportunity for future growth. 
Via InvestorPlace
Italy Probes European Pharma Giants Novartis, Roche Over Eye Drug Competition Allegations
Italy's antitrust authority is investigating Novartis and Roche's Genentech for allegedly delaying the Italian market launch of Byooviz, a Samsung Bioepis biosimilar of Lucentis. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
42 43 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.